CRBP — Corbus Pharmaceuticals Holding
NASDAQ · Healthcare · Biotechnology
$10.95
-$0.33 (-2.97%)
Corbus Pharmaceuticals Holding (CRBP) is a biotechnology company listed on NASDAQ. It is led by Yuval Cohen Ph.D., based in 500 River Ridge Drive, Norwood, MA, United States, 02062, with about 28 employees. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Net income was -$23.3M. CRBP currently screens at market cap $102.3M.
Use this CRBP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CRBP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CRBP SEC filings page. Lician reads the product cache first so this HTML stays unique to Corbus Pharmaceuticals Holding even when a live quote feed is slow.
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Key Statistics
Market Cap
$102.30M
Volume
583,077
Previous Close
$11.13
Day Range
$10.74 – $11.29
EPS
-$3.68
Revenue
$0.00
Net Income
-$40.21M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
28
CRBP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $881.71K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$40.21M | -$44.60M | -$42.35M | -$45.64M |
| EPS (Diluted) | -$3.68 | -$10.31 | -$10.15 | -$11.15 |
Total Assets
$155.88M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$17.20M
Operating Cash Flow
-$41.79M
Free Cash Flow
$0.00
Corbus Pharmaceuticals Holding Company Information
- CEO & Director
- Yuval Cohen Ph.D.
- Headquarters
- 500 River Ridge Drive, Norwood, MA, United States, 02062
- Website
- www.corbuspharma.com
- Phone
- 617 963 0100
- IPO / Founded
- 2014-11-11
- Sector
- Healthcare
- Industry
- Biotechnology